Phase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE)
Yosuke Kawashima(Sendai Kousei Hospital), Hiroshi Kagamu(Saitama International Medical Center), Keigo Kobayashi(Osaka Gakuin University), Ou Yamaguchi(Saitama International Medical Center), Toshiyuki Harada(Hokkaido hospital), Kenichi Yoshimura(Hiroshima University), Futoshi Kurimoto(Saitama Cancer Center), Masahiro Seike(Nippon Medical School Hospital), Takae Okuno(Shimane University), Toshiyuki Kozuki(Shikoku Cancer Center), Naoki Furuya(St. Marianna University School of Medicine), Nobuhisa Ishikawa(The University of Tokyo), Tadaaki Yamada(Kyoto Prefectural University of Medicine), Yuzo Nagai(Saint John's Health Center), Ryo Ko(Shizuoka Cancer Center), Kana Watanabe(Miyagi Prefectural Hospital Organization), Kenichiro Komiyama
Cited by 0
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|642
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
|Annals of Oncology|2012|555
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
|Journal of Clinical Oncology|2019|490